Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced that Noema Pharma, has raised an oversubscribed CHF 103 million Series B financing round.

Scroll to Top